Steris Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Steris Plc (STE31) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Steris Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 4,466M vs 11,524M combined for tracked competitors (27.9% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (-0.4% annualized vs trailing 12 months), vs decelerating (-19.8%) for its tracked peer group.
- Growth: Steris Plc generated -8.0% revenue growth year over year in Q3 2022, vs 89.0% for its tracked competitors combined.
- Profitability: Its 11.1% net margin compares with 10.0% for the peer group.
- Peer revenue share: Steris Plc accounted for 32.5% of combined revenue among its tracked peer group, down from 49.7% a year earlier.
- Peer differentiation: Revenue per employee of $0.32M compares with $0.31M for the peer group (1.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
STE31 Sales vs. its Competitors, Q3 2022
Steris Plc reported revenue contraction of 7.99 % year on year in Q3 2022, below its competitors' combined revenue growth of 89.03 %.
With a net margin of 11.09 %, Steris Plc achieved higher profitability than its competitors (10.02 %).
Steris Plc generated 32.51 % of the combined sales of its peer group, down from 49.74 % a year earlier.
Steris Plc vs. its Competitors, Q3 2022
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Steris Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Steris Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Steris Plc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 15.0% year over year, combined, vs -8.0% for Steris Plc. Steris Plc's share of combined industry revenue moved from 1.19% to 0.95%, a loss of 0.24 percentage points.
Steris Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Steris Plc | Yes | Yes | No | No |
| Competitors combined (5) | ||||
| High-Confidence Competitors (9) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 25.00 % (2 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
STE31 Stock Performance relative to its Competitors
STE31 Stock Performance relative to High-Confidence Competitors
STE31 Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Tomi Environmental Solutions Inc | 282.9% | Outperformed |
| 2 | Integra Lifesciences Holdings Corp | 282.9% | Outperformed |
| 3 | Aptargroup inc | 282.9% | Outperformed |
| 4 | Steris Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Steris Plc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Steris Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Steris Plc | - | 4,465.70 |
| Steris Plc | 20,825.70 | 5,935.90 |
| Aptargroup inc | 7,990.69 | 3,933.24 |
| Integra Lifesciences Holdings Corp | 1,271.79 | 1,647.67 |
| Tomi Environmental Solutions Inc | 10.33 | 6.93 |
| Motus Gi Holdings Inc | 0.00 | 0.33 |
| SUBTOTAL | 30,098.51 | 15,989.77 |
Sources: Steris Plc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Steris Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Steris Plc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Owens & Minor | Named by the company | 85% |
| Skytron | Named by the company | 85% |
| Techniplast | Named by the company | 85% |
| Belimed | Named by the company | 85% |
| Contec | Named by the company | 85% |
| Getinge | Named by the company | 85% |
| Northfield | Named by the company | 85% |
| Rentex Floren | Named by the company | 85% |
| Stilmas | Named by the company | 85% |
| Baxter | Named by the company | 85% |
| Cantel Medical | Named by the company | 85% |
| Fedegari | Named by the company | 85% |
| MECO | Named by the company | 85% |
| Pentax | Named by the company | 85% |
| SteelCo | Named by the company | 85% |
| Wassenburg | Named by the company | 85% |
| Berendsen plc | Named by the company | 85% |
| Crothall | Named by the company | 85% |
| Hill-Rom | Named by the company | 85% |
| Olympus | Named by the company | 85% |
| Ruhof | Named by the company | 85% |
| Stryker | Named by the company | 85% |
| BBraun | Named by the company | 85% |
| CleanLease (Clean Lease Fortex) | Named by the company | 85% |
| Fortive | Named by the company | 85% |
| Mobile | Named by the company | 85% |
| Rentex Awé | Named by the company | 85% |
| Sterilog Limited | Named by the company | 85% |
| Agiliti | Named by the company | 85% |
| Boston Scientific | Named by the company | 85% |
| Ecolab | Named by the company | 85% |
| Karl Storz | Named by the company | 85% |
| Steris Plc | Named by the company | 85% |
| Integra Lifesciences Holdings Corp | Named by the company | 85% |
| Tomi Environmental Solutions Inc | Named by the company | 85% |
| Motus Gi Holdings Inc | Named by the company | 85% |
| Aptargroup inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Steris Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Steris Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Steris Plc | Healthcare 70.23 % |
| Aptargroup inc | Pharma 44.65 % |
| Integra Lifesciences Holdings Corp | Specialty Surgery 73.85 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Steris Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Steris Plc | - | 318,979 | -2,078 |
| Steris Plc | 20,826 | 326,525 | 43,187 |
| Aptargroup inc | 7,991 | 280,946 | 25,920 |
| Integra Lifesciences Holdings Corp | 1,272 | 372,186 | -1,636 |
| Tomi Environmental Solutions Inc | 10 | 346,470 | -172,442 |
| Motus Gi Holdings Inc | 0 | 10,548 | -519,419 |
| PEERS TOTAL | 30,099 | 314,376 | 30,586 |
Steris Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Steris Plc | United States 73.06 % |
| Aptargroup inc | Europe 50.76 % |
| Integra Lifesciences Holdings Corp | United States 73.34 % |
| Tomi Environmental Solutions Inc | International 15.09 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Steris Plc's Strategic Group Map
Every company in Steris Plc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Steris Plc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Steris Plc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Steris Plc falls in the Medium attractiveness / Medium strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Steris Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
No rule matched.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-19.8% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Steris Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Steris Plc | 0.16 | 2.07 | 0.48 |
| Steris Plc | 0.15 | 2.15 | 0.27 |
| Aptargroup inc | 0.22 | 1.50 | 0.61 |
| Integra Lifesciences Holdings Corp | 0.61 | 3.12 | 1.87 |
| Tomi Environmental Solutions Inc | 0.02 | 1.42 | 2.84 |
| Motus Gi Holdings Inc | 1.55 | 1.80 | 6.79 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Steris Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Steris Plc | Q4 2022 | -8.0 % | -13.8 % |
| Steris Plc | Q1 2026 | +7.3 % | +50.8 % |
| Aptargroup inc | Q2 2026 | +6.3 % | -21.2 % |
| Integra Lifesciences Holdings Corp | Q2 2026 | +0.8 % | - |
| Tomi Environmental Solutions Inc | Q2 2026 | +117.9 % | - |
| Motus Gi Holdings Inc | Q1 2024 | +14.3 % | - |
| PEERS TOTAL | +1.9 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Steris Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Steris Plc | Q4 2022 | -5.5 % | -16.1 % |
| Steris Plc | Q1 2026 | +6.2 % | - |
| Aptargroup inc | Q2 2026 | +23.6 % | -10.9 % |
| Integra Lifesciences Holdings Corp | Q2 2026 | -3.5 % | -38.9 % |
| Tomi Environmental Solutions Inc | Q2 2026 | +143.4 % | -78.9 % |
| Motus Gi Holdings Inc | Q1 2024 | +33.3 % | - |
Steris Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Steris Plc | - | - | - |
| Steris Plc | 7.53% | 7.97% | 11.29% |
| Aptargroup inc | 7.05% | 8.83% | 13.48% |
| Integra Lifesciences Holdings Corp | - | - | - |
| Tomi Environmental Solutions Inc | - | - | - |
| Motus Gi Holdings Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Steris Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Steris Plc | - | - |
| Steris Plc | 26.64 | 3.51 |
| Aptargroup inc | 22.59 | 2.03 |
| Integra Lifesciences Holdings Corp | - | 0.77 |
| Tomi Environmental Solutions Inc | - | 1.49 |
| Motus Gi Holdings Inc | - | 0.01 |
| PEERS AVERAGE | 27.56 | 1.88 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.